Drugs / lysine acetylsalicylate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT02243137 | May 2013 → Jun 2014 | — | David Vivas | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT01935193 | Nov 2011 → Aug 2013 | aspirin resistance | Azienda Ospedaliera San Giovanni Battista | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT03370705 Background | Jan → Dec 2019 | peripheral arterial occlusive disease 1 | Alfa Wassermann Tunisia | Unknown | No outcome recorded |
| Phase 3 | NCT02817789 Comparator | May 2016 → May 2018 | aortic valve stenosis | University Hospital, Bordeaux | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lysine acetylsalicylate | “lysine acetylsalicylate or equivalent” NCT03370705 ↗ |
| Action | Inhibit | “stronger cyclooxygenase inhibition with intravenous lysine acetylsalicylate (LA)” PMID 25957056 ↗ May 2015 |
| Route | Intravenous | “endovenous infusion of lysine acetylsalicylate” NCT01935193 ↗ |